NeoGenomics, Inc. (NEO) — ESG & Values Scores

Environment story

NeoGenomics operates clinical laboratories with minimal direct manufacturing footprint, typical of service-based diagnostics companies. Scope 1 and Scope 2 emissions disclosures are absent from filed documents, resulting in a substantial penalty. No net-zero target year is disclosed. The company faces business continuity risks from climate-related weather disruptions (hurricanes in Florida headquarters) but has not disclosed climate adaptation infrastructure investments or renewable energy commitments. No major environmental controversies (toxic waste, water disputes) are evident in filed risk factors. The company's primary environmental impact is indirect—through energy consumption in lab operations and sample transportation (FedEx reliance). Absence of environmental strategy, carbon accounting, or sustainability targets prevents higher scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Climate Risk Awareness

10-K acknowledges increased frequency/severity of hurricanes as climate-change risk to Florida headquarters and other facilities.

Identified risk but no mitigation infrastructure (e.g., backup generators) deployed at Tampa, Nashville, Atlanta, Phoenix dry-lab locations.
Environmental & Health Safety Compliance

Company maintains compliance programs for hazardous/biological waste handling, regulated under federal/state environmental laws. Employee Health & Safety Department monitors use of hazardous materials.

Operational hygiene; not decarbonization-focused.

Social story

NeoGenomics demonstrates moderate social performance with no disclosed union-suppression activities or major strikes within 24 months. Leadership diversity metrics are not publicly disclosed in the 10-K, limiting assessment of executive/board representation. No CEO-to-median-worker pay ratio disclosed. The company operates under robust HIPAA, HITECH, and GDPR compliance frameworks protecting patient privacy and genetic information. Supply chain risks related to laboratory reagent and equipment suppliers from third parties (e.g., sequencer manufacturers) are acknowledged but audits for human-rights hazards are not described. No disclosed forced-labor, conflict-minerals, or modern-slavery policies. Employee turnover rate is undisclosed. Positive factors include robust compliance and ethics program with anonymous hotline, retaliation prohibition, and regular Audit Committee oversight. The company emphasizes quality of care and employee commitment to reliable services.

Criticisms on file

Dependence on key personnel; turnover risk. Loss of sales representatives could result in loss of client goodwill and competitive vulnerability.
Source: NEO 10-K, Risk Factors: 'We are dependent on key personnel and need to hire additional qualified personnel in order for our business to succeed.'

Disclosed initiatives

Compliance & Ethics Program

Robust program encompassing OIG guidance, fraud alerts, and advisory opinions. Employees can report violations anonymously via hotline 24/7/365. Vice President of Compliance & Privacy investigates and reports to Audit Committee. Strict retaliation prohibition.

Reduces fraud/abuse risk; supports regulatory compliance.
Quality Management System

Standard operating procedures, performance measurement, reporting mechanisms. Employees trained on reliable and consistent service delivery. Tests frequently revised and improved.

Patient safety and service quality maintained.
Personnel Development

Risk factor acknowledges intense competition for qualified sales, technical, and managerial personnel. Company invests in hiring and training.

Workforce retention and capability building; high recruitment costs noted as ongoing challenge.

Governance story

NeoGenomics exhibits adequate governance with no disclosed dual-class share structure limiting voting equity. Board independence percentage is not disclosed in filed documents. No active lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks are disclosed. However, the company faces significant regulatory and litigation risks: (1) IP litigation costs ($11.3M in 2025, $13.8M in 2024) including RaDaR ST patent dispute (resolved Dec 2025); (2) FDA regulatory uncertainty regarding Laboratory Developed Tests (LDTs)—the company challenged FDA's May 2024 final rule through industry consortia (ACLA, AMP), which was vacated by court in March 2025; (3) extensive compliance obligations under Anti-Kickback Statute, Stark Law, False Claims Act, HIPAA, GDPR, and state privacy laws. No antitrust proceedings disclosed. The company maintains Audit Committee oversight of compliance. CEO transition in 2025 cost $3.5M (severance, retention, search). Risk factors acknowledge potential for future regulatory burdens.

Criticisms on file

IP Litigation: RaDaR ST patent dispute. Resolved with no remaining claims in December 2025; cumulative settlement costs $11.3M (2025) and $13.8M (2024).
Source: NEO 10-K MD&A: '2025 Overview and Highlights: We successfully resolved the RaDaR ST patent litigation with no remaining claims pending against the Company in December 2025.'
FDA Regulatory Uncertainty: FDA issued final rule (May 2024) regulating LDTs as medical devices, phasing out enforcement discretion over 4 years. ACLA and AMP filed lawsuits. Court vacated rule (March 2025), but future legislative/regulatory action could reintroduce FDA oversight, increasing compliance obligations and costs.
Source: NEO 10-K Item 1A Risk Factors: 'If the FDA were to begin to regulate Laboratory Developed Tests as medical devices it could require us to conduct additional clinical trials and obtain regulatory approval for our products, which could harm our business.'

Disclosed initiatives

Audit Committee Oversight

Board maintains Audit Committee that meets regularly to discuss compliance issues. Vice President of Compliance & Privacy reports quarterly on program effectiveness.

Enhanced regulatory and compliance governance.
Regulatory Advocacy

Company participated in ACLA and Association for Molecular Pathology lawsuits challenging FDA's LDT final rule (May 2024). Court vacated rule in March 2025.

Preserved regulatory status quo for LDTs under existing CLIA framework; litigation costs material but outcome favorable.
Anti-Kickback & Stark Law Compliance

Company screens third parties, monitors transactions, performs routine audits to ensure Stark Law compliance. Structures physician relationships to comply with federal and state laws.

Reduces fraud/exclusion risk under Medicare/Medicaid.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of NeoGenomics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open NeoGenomics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)